LAWRENCEVILLE, N.J., Feb. 16 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced
The company's comprehensive portfolio of well-established specialty pharmaceuticals targets cardiovascular (Mephyton®, Edecrin®, Sodium Edecrin®), metabolic (Cuprimine®, Syprine®, Demser®) and ophthalmic (Lacrisert® and the Timoptic® product line) diseases.
With more than 30 years of experience in clinical operations, Dr. Mulcahy has been responsible for the development and management of clinical programs across a range of therapeutic classes, including cardiovascular and CNS disorders, experience which is highly relevant to the clinical programs he will lead for Aton.
"Dr. Mulcahy's extensive scientific, clinical and regulatory background will provide exemplary leadership for Aton's burgeoning pipeline of development programs," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "His technical acumen and strong track record of NDA submissions will help Aton fulfill its mission of bringing innovative and medically necessary medications to patients in need around the world."
Prior to joining Aton, Dr. Mulcahy served as Vice President of Research and Development at Alita Pharmaceuticals, as Vice President of Clinical Operations at the Duramed Research subsidiary of Barr Pharmaceuticals and as Senior Director of Scientific and Regulatory Affairs at Teva Pharmaceuticals North America. He began his pharmaceutical career at Merck Research Laboratories where he was awarded a Doctoral Study Fellowship. Dr. Mulcahy earned his Ph.D. in pharmacology from Temple University School of Medicine, an M.S. from Drexel University and his B.A. from Arcadia University.
About Aton Pharma, Inc.
Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.
SOURCE Aton Pharma, Inc.
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All